Driven by technology, supported by data, focused on insight.
Our discovery pipeline combines next-generation mass spectrometry technology, computational analysis, and large-scale human biology data.
Advancing precision medicine demands greater discovery of biomarkers that improve our understanding of complex diseases and identify patients most likely to benefit from specific treatments. Sapient’s platform, built on proprietary next-gen mass spec systems and an expansive Human Biology Database, multiplies the rate of small molecule biomarker discovery to help biopharma sponsors maximize drug development success.
Sapient’s Core Technology
Take a closer look at our platform.
Leverage Sapient’s method for untargeted biomarker profiling to significantly amplify your discovery potential. Then use our expert data science team and vast human chemical databases to interpret, validate, and translate those discoveries for clinical impact.
Sapient’s next-generation rapid liquid chromatography-mass spectrometry (rLC-MS) infrastructure and automated workflows scale the speed and capacity of current analytical technologies, assaying >15,000 small molecule biomarkers per biosample in less than 1 minute per sample. Using untargeted molecular profiling, these systems enable discovery of uncharacterized compounds.
Applying statistical and machine learning tools to the generated data, Sapient’s expert data science team enables identification of key molecules that provide actionable insights for your drug development program, such as biomarkers of target engagement, biological processes, disease progression, or adverse events.
Human Biology Database
Sapient’s expansive repository is comprised of data from 100,000+ human biosamples, including >10-30 years of follow-up information across patients. We use this data to amplify discovery potential, to confirm biomarker findings in independent samples and to validate preclinical and clinical discoveries.
Collectively, these technologies enable Sapient to:
Identify key biological mechanisms of disease
Confirm pharmacological engagement of key targets
Provide early insight into potential drug safety risks
Uncover dosing and timing of drug targets
Align patients, disease biology, and specific therapies
A Culture of Quality
Consistency, collaboration, and radical transparency.
We pride ourselves on upholding rigorous quality standards and adhere to stringent regulatory standards in practice. Upon identifying biomarkers interest through our rLC-MS discovery screening, we can employ more traditional targeted methods to confirm key signals and develop specific metabolites or lipids into clinical assays for use in GLP or CLIA settings.
Our high complexity CLIA-certified, CAP-accredited laboratory supports rapid translation of the biomarker discoveries we make for our biopharma customers to regulated clinical applications.